Date
7月3日

7月10日

Presenter
榊

7月24日

7月31日

9月4日

for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

一瀬Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Blood

2018

131

1698-1703

Blood

2018

131

2978-2986.

201819889-903

古本

Impact of gut colonization with butyrate-producingmicrobiota on respiratory viral infection following
allo-HCT
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid
leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

2018

132

49－58

田口

Somatic mutations precedo acute myeloid leukemia years before diagnosis

Nature medicine

2018

24

1015-1023

prediction of acute myeloid leukemia risk in healthy individuals

Nature2018559

400-404

宮崎

Consequences of mutant TET2 on clonality and subclonal hierarchy

Leukemia

201832

1751-1761

北之園

Epigenetic silencing of miR-125b is required for normal B-cell development

Blood

2018

131

1920－1930

今泉

JCOG班会議の報告

北之園

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Cell report

2018242155ｰ2166

Leukemia

201832

1482ｰ1492

Am J Hematology

201893921-930

N Engl J Med

2018

379

811ｰ822

J Clin Oncol.

2017

35

32-39

N Engl J Med

2018

379

934－947

Cell

2018

175

171－185

Nature2018561

473ｰ478

Leukemia

2018

Blood Adv.

2018

23

2619ｰ2628

2018

131

1522ｰ1531

2018

24

1463-1470.

Cancer Cell.

2018

34

286-297

Blood.

2018132

2026-2039

J Clin Oncol.

2018

36

2918-2925

N Engl J Med

2018

378

2386-2398

榊Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic
syndrome and acute myeloid leukemia: are we there yet?
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results oftwo phase 3, randomized, placebo-controlled trials.

橋本

日本血液学会予行

坂本

日本血液学会予行

一瀬

Between 2000 and 2013: A Cooperative Study in Japan.
日本血液学会予行

古本

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

10月16日

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in
Preclinical Models.
血液学会

田口
波多
長井藤岡

坂本

澤山

田口
今泉
北之園
宮崎

11月27日Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed波多

安東

11月20日Oncology

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood

9月25日

11月13日Lancet学生

日本血液学会予行

11月6日

871－879
600-607藤岡

10月30日

1922

9月18日

10月23日

2018

Page

2018

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

10月9日

Oncology

Vol

Cell stem cell

佐藤

10月2日

LancetYear

Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment.

糸永
9月11日

JournalOral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid

長井沢山

7月17日

Title

榊佐藤

報告会

Population dynamics of normal human blood inferred from somatic mutations
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia
and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Complement-mediated thrombotic microangiopathy as a link between endothelial damage andsteroid-refractory GVHD.
Lymphocyte-Area Under the Curve as a predictive factor for viral infection after allogenic

Biol Blood Marrow

hematopoietic stem cell transplantation.

Transplant.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic
leukemia.

Blood.

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, aBiol Blood Marrow

Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation.

Transplant.

2018

ASH予行
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell
Leukemia/Lymphoma.
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation andlymphoma cell survival
ASHの講演内容の紹介
Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage
Follicular Lymphoma: TROG 99.03.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML